Vitamin Shoppe, Inc (NYSE:VSI) – Research analysts at Gabelli dropped their FY2021 earnings estimates for shares of Vitamin Shoppe in a research report issued on Thursday. Gabelli analyst D. Witkowski now anticipates that the specialty retailer will earn $1.10 per share for the year, down from their previous estimate of $1.15.

Several other analysts also recently weighed in on VSI. ValuEngine upgraded Vitamin Shoppe from a “hold” rating to a “buy” rating in a report on Thursday, October 5th. Morgan Stanley set a $8.00 price objective on Vitamin Shoppe and gave the company a “hold” rating in a report on Thursday, August 10th. Bank of America Corporation restated an “underperform” rating and issued a $5.00 price objective (down from $5.50) on shares of Vitamin Shoppe in a report on Wednesday, August 23rd. Zacks Investment Research upgraded Vitamin Shoppe from a “sell” rating to a “hold” rating in a report on Wednesday, October 25th. Finally, Barclays PLC decreased their price objective on Vitamin Shoppe from $13.00 to $6.00 and set an “equal weight” rating for the company in a report on Thursday, August 10th. Four analysts have rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $5.00.

COPYRIGHT VIOLATION NOTICE: “Gabelli Weighs in on Vitamin Shoppe, Inc’s FY2021 Earnings (VSI)” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.watchlistnews.com/gabelli-weighs-in-on-vitamin-shoppe-incs-fy2021-earnings-vsi/1696198.html.

Vitamin Shoppe (NYSE VSI) remained flat at $$3.50 during trading hours on Friday. The company’s stock had a trading volume of 709,300 shares, compared to its average volume of 511,542. Vitamin Shoppe has a 1-year low of $2.95 and a 1-year high of $26.60. The firm has a market capitalization of $83.92, a P/E ratio of 3.76 and a beta of 0.74. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.07 and a quick ratio of 0.34.

Vitamin Shoppe (NYSE:VSI) last released its earnings results on Wednesday, November 8th. The specialty retailer reported ($0.03) earnings per share for the quarter, missing the consensus estimate of $0.17 by ($0.20). Vitamin Shoppe had a positive return on equity of 6.17% and a negative net margin of 20.27%. The business had revenue of $288.20 million for the quarter, compared to the consensus estimate of $297.61 million. During the same quarter last year, the business posted $0.50 earnings per share. The firm’s revenue for the quarter was down 8.5% compared to the same quarter last year.

Several hedge funds have recently modified their holdings of the company. Trexquant Investment LP purchased a new stake in Vitamin Shoppe in the third quarter valued at approximately $243,000. GMT Capital Corp purchased a new stake in Vitamin Shoppe in the third quarter valued at approximately $3,423,000. Systematic Financial Management LP boosted its position in Vitamin Shoppe by 94.9% in the third quarter. Systematic Financial Management LP now owns 217,345 shares of the specialty retailer’s stock valued at $1,163,000 after buying an additional 105,855 shares during the last quarter. Dynamic Technology Lab Private Ltd boosted its position in Vitamin Shoppe by 335.7% in the third quarter. Dynamic Technology Lab Private Ltd now owns 77,389 shares of the specialty retailer’s stock valued at $414,000 after buying an additional 59,628 shares during the last quarter. Finally, Macquarie Group Ltd. purchased a new stake in Vitamin Shoppe in the third quarter valued at approximately $101,000. Institutional investors and hedge funds own 98.39% of the company’s stock.

In other Vitamin Shoppe news, Director John D. Bowlin purchased 40,000 shares of the company’s stock in a transaction dated Friday, August 25th. The shares were acquired at an average price of $5.50 per share, for a total transaction of $220,000.00. Following the completion of the purchase, the director now owns 56,028 shares of the company’s stock, valued at $308,154. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. 1.07% of the stock is currently owned by insiders.

Vitamin Shoppe Company Profile

Vitamin Shoppe, Inc (VSI) is a multi-channel specialty retailer and contract manufacturer of vitamins, minerals, herbs, specialty supplements, sports nutrition, and other health and wellness products. The Company operates through three segments: retail, direct and manufacturing. The retail segment includes Vitamin Shoppe, Super Supplements and Vitapath retail store formats.

Earnings History and Estimates for Vitamin Shoppe (NYSE:VSI)

Receive News & Ratings for Vitamin Shoppe Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitamin Shoppe Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.